


## Immuno-Oncology Profiling Services

### Efficacy Profiling of Cancer Immunotherapies

- Our cancer immunotherapy platform is based on 3D co-culture models from patient-derived microtumors (PDMs) + autologous immune cells
- We have successfully established an ever-growing panel of 3D co-culture models for a variety of cancer types (renal cell carcinoma, colorectal, bladder, prostate, NSCLC, other entities in progress)
- 3D microtumor cultures are ready for compound testing in 96-well format within 2 weeks after isolation from tumor tissue
- All assays are amenable to mono and combinatorial dose-response testing, i.e., by targeted and cell-based approaches, antibodies, etc.



### Compound Testing in Patient-Derived 3D Tumor/Immune Cell Models

- Selective live cell labeling, dye release based cytotoxicity analyses
- Time-resolved high-content analysis of microtumor infiltration by T lymphocytes
- Proteomics add-ons: Multiplex Luminex cytokine assays, DigiWest protein profiling
- Genomics add-ons: Multiplex RT-qPCR panel assays
- Studies are offered on a fee-for-service basis and are fully customizable

